ZymoGenetics Presents Positive Results From RECOTHROM(TM) Thrombin, Topical (Recombinant) Spray Study In Burn Patients

ZymoGenetics, Inc. (NASDAQ:ZGEN), presented results at the American Burn Association annual meeting from a clinical trial with RECOTHROM? Thrombin, topical (Recombinant) administered by spray device to burn wound excision sites. The study evaluated the safety and immunogenicity of RECOTHROM for patients undergoing skin grafting for burns.

More: continued here

Filed under: Dermatology on May 15th, 2008